Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
584
datasets available to search
ShareScore release 0.9.0
Dataset results
584 results for “Osteosarcoma”
Combined bioinformatics and machine learning methodologies reveal prognosis-related ceRNA network and propose ABCA8, CAT, and CXCL12 as independent protective factors against osteosarcoma
<p><strong>Supplementary Table 1</strong>. Basic traits of the seven microarray datasets from the Gene Expression Omnibus and The Cancer Genome Atlas.</p><p><strong>Supplementary Table 2</strong>. Basic characteristics of the nine differentially expressed circRNAs</p><p><strong>Supplementary Table 3</strong>. Index of concordance (C-index) and variance inflation factor (VIF) of ABCA8, CXCL12, and CAT.</p><p><strong>Supplementary Table 4.</strong> LASSO and cox analysis of ceRNA with coef/se(coef) < 0.01 and P-value of proportional hazards assumption (PH) > 0.05.</p><p><strong>Supplementary Table 5</strong>. Robust rank aggregation analysis of ABCA8, CXCL12, and CAT. LogFC in the four datasets and RRA score of the three RNAs.</p><p><strong>Supplementary Figure 1.</strong> Competitive endogenous RNA in osteosarcoma.</p><p><strong>Supplementary Figure 2.</strong> Protein–protein interaction (PPI) network of genes in the competitive endogenous RNA network</p><p><strong>Supplementary Figure 3.</strong> Proportional hazards assumption (left) and linearity assumption (right).</p><p><strong>Supplementary Figure 4.</strong> Survival analysis for competitive endogenous RNA in osteosarcoma.</p>
Inhibition of DKK-1 Limits Osteosarcoma Metastasis in a Clinically Relevant Mouse Model
<p>Single-cell RNA-seq data of untreated (F43N, F43R) and DKK-1 inhibitor treated (OSW3, OSW4, OSW5, OSW6) patient derived xenografts (PDXs). </p> <p>human_cells_scanpy_object.h5ad -- contains Scanpy analysis of human cells from untreated and DKK-1 inhibitor treated PDXs</p> <p>raw_counts_cellranger_output.zip -- contains the raw expression counts of untreated and DKK-1 inhibitor treated PDXs cells outputted by CellRanger. </p>
Raw Data for the article: Potential Anti-Metastatic Role of the Novel miR-CT3 in Tumor Angiogenesis and Osteosarcoma Invasion
<p>Osteosarcoma (OS) is the most common primary bone tumor mainly occurring in young adults and derived from primitive bone-forming mesenchyme. OS develops in an intricate tumor microenvironment (TME) where cellular function regulated by microRNAs (miRNAs) may affect communication between OS cells and the surrounding TME. Therefore, miRNAs are considered potential therapeutic targets in cancer and one of the goals of research is to accurately define a specific signature of a miRNAs, which could reflect the phenotype of a particular tumor, such as OS. Through NGS approach, we previously found a specific molecular profile of miRNAs in OS and discovered 8 novel miRNAs. Among these, we deepen our knowledge on the fifth candidate renamed now miR-CT3. MiR-CT3 expression was low in OS cells when compared with human primary osteoblasts and healthy bone. Through TargetScan, VEGF-A was predicted as a potential biological target of miR-CT3 and luciferase assay confirmed it. We showed that enforced expression of miR-CT3 in two OS cell lines, SAOS-2 and MG-63, reduced expression of VEGF-A mRNA and protein, inhibiting tumor angiogenesis. Enforced expression of miR-CT3 also reduced OS cell migration and invasion as confirmed by soft agar colony formation assay. Interestingly, we found that miR-CT3 behaves inducing the activation of p38 MAP kinase pathway and modulating the epithelial-mesenchymal transition (EMT) proteins, in particular reducing Vimentin expression. Overall, our study highlights the novel role of miR-CT3 in regulating tumor angiogenesis and progression in OS cells, linking also to the modulation of EMT proteins.</p>
Payload-delivering engineered γδ T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma
<p>T cell-based cancer immunotherapy has typically relied on membrane-bound cytotoxicity enhancers such as chimeric antigen receptors expressed in autologous αβ T cells. These approaches are limited by tonic signaling of synthetic constructs and costs associated with manufacturing. γδ T cells are an emerging alternative for cellular therapy, possessing innate anti-tumor activity, potent antibody-dependent cellular cytotoxicity, and minimal alloreactivity. We present an immunotherapeutic platform technology built around the innate properties of the Vγ9Vδ2 T cell, harnessing specific characteristics of this cell type and offering an allo-compatible cellular therapy that recruits bystander immunity. We engineered γδ T cells to secrete synthetic tumor-targeting opsonins in the form of an scFv-Fc fusion protein and a mitogenic IL-15Ra–IL-15 fusion protein (stIL15). Using GD2 as a model antigen, we show that GD2-specific opsonin-secreting Vγ9Vδ2 T cells (stIL15-OPS-γδ T cells) have enhanced cytotoxicity and promote bystander activity of other lymphoid and myeloid cells. Secretion of stIL-15 abrogated the need for exogenous cytokine supplementation and further mediated activation of bystander natural killer cells. Compared to unmodified γδ T cells, stIL15-OPS-γδ T cells exhibited superior in vivo control of subcutaneous tumors and persistence in the blood. Moreover, stIL15-OPS-γδ T cells were efficacious against patient-derived osteosarcomas in animal models and in vitro, where efficacy could be boosted with the addition of zoledronic acid. Together the data identify stIL15-OPS-γδ T cells as a candidate allogeneic cell therapy platform combining direct cytolysis with bystander activation to promote tumor control.</p>
Osteosarcoma-enriched transcripts paradoxically generate osteosarcoma-suppressing extracellular proteins
<p>Osteosarcoma (OS) is the common primary bone cancer that affects mostly children and young adults. To augment the standard-of-care chemotherapy, we examined the possibility of protein-based therapy using mesenchymal stem cells (MSCs)-derived proteomes and osteosarcoma-elevated proteins. While a conditioned medium (CM), collected from MSCs, did not present tumor-suppressing ability, the activation of PKA converted MSCs into induced tumor-suppressing cells (iTSCs). In a mouse model, the direct and hydrogel-assisted administration of CM inhibited tumor-induced bone destruction, and its effect was additive with Cisplatin. CM was enriched with proteins such as Calreticulin, which acted as an extracellular tumor suppressor by interacting with CD47. Notably, the level of Calr transcripts was elevated in OS tissues, together with other tumor-suppressing proteins, including histone H4, and PCOLCE. PCOLCE acted as an extracellular tumor-suppressing protein by interacting with amyloid precursor protein (APP), a prognostic OS marker with poor survival. The results supported the possibility of employing a paradoxical strategy of utilizing OS transcriptomes for the treatment of OS.</p>
Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
ClinicalTrials.gov study NCT00066365. IPD Sharing: Not stated. Countries: 4. Publications: 1.
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
ClinicalTrials.gov study NCT04154189. IPD Sharing: YES. Countries: 21. Publications: 3.
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
ClinicalTrials.gov study NCT00102531. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma
ClinicalTrials.gov study NCT01886105. IPD Sharing: NO. Countries: 1. Publications: 26.
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
ClinicalTrials.gov study NCT00667342. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignan
ClinicalTrials.gov study NCT00716976. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
ClinicalTrials.gov study NCT03860207. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
ClinicalTrials.gov study NCT00134030. IPD Sharing: Not stated. Countries: 6. Publications: 4.
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
ClinicalTrials.gov study NCT01833520. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
ClinicalTrials.gov study NCT02517918. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
ClinicalTrials.gov study NCT01848457. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
ClinicalTrials.gov study NCT02487979. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
ClinicalTrials.gov study NCT02432274. IPD Sharing: Not stated. Countries: 6. Publications: 4.
Epigenetic Biomarker for Osteosarcoma
ClinicalTrials.gov study NCT03336554. IPD Sharing: UNDECIDED. Countries: 1. Publications: 12.
Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
ClinicalTrials.gov study NCT00245011. IPD Sharing: Not stated. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.